AstraZeneca Pharma India Limited and Mankind Pharma Limited have forged a groundbreaking partnership aimed at revolutionizing asthma treatment accessibility in India. With India contributing a staggering 13% to the global asthma burden and a disproportionate 43% of global asthma deaths, this collaboration comes as a beacon of hope for millions grappling with this respiratory condition across the nation.

Under the terms of the agreement, AstraZeneca’s renowned budesonide and formoterol fumarate dihydrate combination, marketed under the brand name Symbicort, will be exclusively distributed by Mankind Pharma in India. AstraZeneca will retain the intellectual property rights to these essential medications, ensuring quality and adherence to global standards. Dr. Sanjeev Panchal, Country President and Managing Director of AstraZeneca India, expressed enthusiasm about the partnership, stating, “The partnership with Mankind Pharma presents an opportunity to accelerate access and maximize the potential of our asthma drug. We are equally invested in improving access strategically across the country.”

Symbicort, renowned for its dual mechanism of action and user-friendly inhaler design, has been hailed as a game-changer in asthma management globally. Atish Majumdar, Sr. President of Sales & Marketing at Mankind Pharma, echoed this sentiment, highlighting the significance of Symbicort in enhancing patient outcomes. “We are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating Asthma,” said Majumdar. “Through our field forces’ extensive outreach, we hope to strengthen access across urban and rural markets.”

This collaboration marks a significant step towards bridging the gap in asthma management in India, aligning with both companies’ commitment to prioritizing patient well-being. By leveraging AstraZeneca’s expertise in respiratory medications and Mankind Pharma’s extensive distribution network, the partnership aims to empower patients nationwide with access to cutting-edge asthma treatments.

As India grapples with the burden of asthma-related morbidity and mortality, this alliance offers a ray of hope for millions, promising improved quality of life and better health outcomes for asthma patients across the country. With a shared vision of putting patients first, AstraZeneca and Mankind Pharma exemplify the power of collaboration in driving positive change in healthcare delivery.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.